19 June 2013
Keywords: promising, ph, ii, data, genzyme/bayer, alemtuzumab, findings
Article | 27 October 2008
Findings from a mid-stage study suggest that leukemia drug Campath (alemtuzumab) can have a large and durable impact on patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 October 2008
18 June 2013
© 2013 thepharmaletter.com